Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) crossed above its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $3.87 and traded as high as $3.89. Armata Pharmaceuticals shares last traded at $3.89, with a volume of 50,548 shares trading hands.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Armata Pharmaceuticals in a report on Tuesday, September 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $15.00.

Armata Pharmaceuticals Trading Up 3.7%

The firm has a market capitalization of $144.63 million, a P/E ratio of -0.51 and a beta of 1.54. The business’s 50 day simple moving average is $3.87 and its two-hundred day simple moving average is $6.87.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last released its earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.17. Armata Pharmaceuticals had a negative net margin of 3,467.04% and a negative return on equity of 12.24%. The company had revenue of $2.51 million during the quarter, compared to analyst estimates of $0.40 million. Analysts predict that Armata Pharmaceuticals, Inc. will post 0.50 EPS for the current fiscal year.

Institutional Trading of Armata Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the company. Madison Asset Management LLC purchased a new position in shares of Armata Pharmaceuticals during the 1st quarter valued at $21,583,000. BlackRock Inc. purchased a new stake in Armata Pharmaceuticals in the 2nd quarter worth $3,629,000. Sei Investments Co. bought a new stake in Armata Pharmaceuticals during the first quarter valued at about $760,000. Bank of New York Mellon Corp bought a new stake in Armata Pharmaceuticals during the second quarter valued at about $193,000. Finally, Nisa Investment Advisors LLC bought a new stake in Armata Pharmaceuticals during the third quarter valued at about $50,000. 3.57% of the stock is currently owned by institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies for drug-resistant bacterial infections. Bacteriophages, or phages, are viruses that selectively infect and destroy specific bacteria, offering a potential alternative or complement to conventional antibiotics. The company’s pipeline has included inhaled and intravenously administered phage candidates designed to treat serious infections caused by pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus .